Annexon (ANNX) vs Collegium Pharmaceutical (COLL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Annexon (ANNX) has outperformed Collegium Pharmaceutical (COLL) over the past year, gaining 30.6% versus a loss of 34.3%. Over five years, COLL leads with a +4.5% price change compared with -81.8% for ANNX. Annexon is the larger company by market cap ($757.4 million vs $718.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | COLL |
|---|---|---|
| Share price | $4.00 | $22.07 |
| Market cap | $757.37M | $718.50M |
| 1-day change | -0.37% | +0.64% |
| YTD return | -20.12% | -52.63% |
| 1-year return | +30.62% | -34.32% |
| 5-year return | -81.77% | +4.53% |
| P/E ratio (TTM) | — | 17.38 |
| Forward P/E | — | 3.32 |
| EPS (TTM) | $-1.13 | $1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.18 | $50.79 |
| 52-week low | $2.54 | $21.43 |
| Distance from 52-week high | -44.36% | -56.54% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +286.23% | +122.02% |
| Average volume | 3.11M | 748.29K |
| Shares outstanding | 189.58M | 32.56M |
| Employees | 92 | 423 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANNX has outperformed COLL by 64.9 percentage points over the past year.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
ANNX vs COLL FAQ
Which is bigger, Annexon or Collegium Pharmaceutical?
Annexon (ANNX) is larger, with a market capitalization of $757.37M compared with $718.50M for Collegium Pharmaceutical (COLL).
Which stock has performed better over the past year, ANNX or COLL?
ANNX returned +30.62% over the past 12 months, compared with -34.32% for COLL (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and Collegium Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.